NewsBenzingaWells Fargo mejora la calificación de enGene Therapeutics a sobreponderar y eleva el precio objetivo a 6 dólares Wells Fargo mejora la calificación de enGene Therapeutics a sobreponderar y eleva el precio objetivo a 6 dólares Benzinga 2026.11.12 12:26 (GMT+0) Open on Benzinga Other news How Tokenized Nvidia Traded Through Two Weeks of Huang Headlines What Are Wall Street Analysts' Target Price for Lumentum Holdings Stock? Texas Pacific Land Stock: Analyst Estimates & Ratings Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66